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Abstract
Transforming growth factor b (TGF-b)i sa
multifunctional cytokine capable of regulating diverse
cellular processes. In this study we investigated the
effect of autocrine TGF-b signaling on tumor necrosis
factor (TNF) a-induced cell death. We abrogated the
TGF-b autocrine loop by overexpression of a truncated
TGF-b type II receptor in MCF-7 breast carcinoma cells
and found that this generated resistance to TNF-a-
induced cytotoxicity. To elucidate the molecular basis
of the influence of TGF-b on TNF-a-induced
cytotoxicity, we evaluated the expression levels or
activities of proteins involved in TNF-a signal
transduction or the regulation of apoptosis in general
in TGF-b-responsive and TGF-b-nonresponsive MCF-7
cells. We observed no significant difference in the
expression of TNF-a receptors or the TNF receptor-
associated death domain protein. In addition,
downstream activation of nuclear factor kB by TNF-a
was not altered in cells that had lost TGF-b
responsiveness. Analysis of members of the Bcl-2
family of apoptosis-regulatory proteins revealed that
Bcl-XL and Bax expression levels were not changed by
disruption of TGF-b signaling. In contrast, the TGF-b-
nonresponsive cells expressed much higher levels of
Bcl-2 protein and mRNA than did cells with an intact
TGF-b autocrine loop. Furthermore, restoration of a
TGF-b signal to MCF-7 cells that had spontaneously
acquired resistance to TGF-b caused a reduction in
Bcl-2 protein expression. Taken together, our data
indicate that loss of autocrine TGF-b signaling results
in enhanced resistance to TNF-a-mediated cell death
and that this is likely to be mediated by derepression
of Bcl-2 expression.
Introduction
TGF-b
4 is a multifunctional peptide growth factor that plays
a pivotal role in many physiological and pathological pro-
cesses. The principle effects of TGF-b include regulation of
cell proliferation, cell migration, cellular differentiation, im-
mune cell behavior, and the synthesis and degradation of the
extracellular matrix (see Refs. 1 and 2 for a general review of
TGF-b). TGF-b elicits its effects by binding and activating
specific receptors expressed on the surface of cells. The
TbR-I and TbR-II are transmembrane serine/threonine ki-
nases directly involved in signal propagation. Because both
ligand and receptors are expressed in many different tissues
and cell types, TGF-b contributes to a wide range of biolog-
ical processes via autocrine and paracrine pathways. The full
measure of the potential complexity of the effects of TGF-b
can come into play during the initiation and progression of
malignancy. Autocrine effects of TGF-b have been impli-
cated in some models of carcinogenesis and local invasion,
whereas paracrine actions of TGF-b may facilitate metastatic
spread and tumor cell escape from immune surveillance (3,
4). Indeed, analysis of the production of TGF-b by tumor
cells, as well as that of the functional status of the TGF-b
signal transduction pathway in tumors, has generated im-
portant insights into tumor cell biology.
Among the least understood aspects of TGF-b biology is its
role in regulating apoptosis and cell death. Many groups have
documented an increase in TGF-b mRNA and/or protein as an
early event in the apoptotic cascade. Examples of increased
TGF-b production by cells undergoing apoptosis include re-
moval of hormone from hormonally dependent epithelia (5–7),
antimetabolite-induced apoptosis of hormone-independent tu-
mor cells (8), and treatment of human mammary carcinomas
with pharmacological doses of antiestrogens (9, 10). What re-
mains unclear, however, is whether the observed rise in TGF-b
is an integral component of the apoptotic cascade or whether
it is simply a consequence of the cytotoxic insult.
An investigation by Danforth and Sgagias (11) attempted
to elucidate the role, if any, of TGF-b as a determinant of cell
death induced by TNF-a. TNF-a is an inflammatory cytokine
capable of binding and activating cell surface receptors
(TNF-RI and TNF-RII). TNF-RI is a member of a family of
death-inducing receptors that includes Fas/CD95 and death
receptor 3. Binding of TNF-a to TNF-RI is responsible for the
generation of many of the known cellular responses of Received 8/15/00; revised 12/19/00; accepted 12/20/00.
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Danforth and Sgagias (11) observed that breast cancer cell
lines that were susceptible to TNF-a-mediated cytotoxicity
exhibited an increase in TGF-b production within 24–48 h
after exposure to TNF-a and before cell death. On coincu-
bation with neutralizing anti-TGF-b antibody, they observed
no suppression of TNF-a-mediated killing and therefore con-
cluded that TGF-b played no critical role in this process.
However, this experimental strategy cannot rule out the pos-
sibility that TGF-b is involved in autocrine regulation of ap-
optosis because exogenous antibody may not gain access
to all of the TGF-b capable of eliciting an effect.
A more definitive test of the hypothesis that an autocrine
effect of TGF-b plays an important role in the TNF-a-
mediated apoptotic death of the cell could be accom-
plished by specific and complete abrogation of the TGF-b
pathway. We therefore transfected MCF-7 cells that are
sensitive to both TGF-b and TNF-a with a truncated TbR-
II. Others have demonstrated that when overexpressed, a
truncated TbR-II acts in a dominant negative fashion, re-
sulting in loss of TGF-b responsiveness (13). Comparison
of the resulting TGF-b-nonresponsive cells to their TGF-
b-responsive counterparts demonstrated that the auto-
crine production of TGF-b sensitizes cells to the cytotoxic
effects of TNF-a. Analysis of TNF-a signaling and expres-
sion of apoptosis-regulating genes in these cells has
implicated TGF-b-mediated repression of Bcl-2 expres-
sion as the potential underlying mechanism for our
observations.
Results
Truncated TbR-II Functions as a Dominant Negative
Inhibitor in MCF-7 Cells. TGF-b-responsive MCF-7 cells
were transfected with a bicistronic mammalian expression
plasmid construct, TREZ, which encodes a truncated TbR-II
sequence lacking the cytoplasmic kinase domain and a zeo-
cin resistance gene for selection, or with a control vector
plasmid, EZ, which encodes the zeocin resistance gene only.
After selection in 50 mg/ml zeocin for 4–6 weeks, zeocin-
resistant clones were isolated, and these stable transfectants
were screened by Western analysis to verify expression of
the truncated TbR-II (Fig. 1). As expected, the MCF-7/TREZ
clones express high levels of truncated TbR-II in addition to
the full-length endogenous TbR-II, whereas the MCF-7/EZ
clones express only the full-length endogenous receptor.
Furthermore, it should be noted that the expression level of
the truncated TbR-II in MCF-7/TREZ clones is many fold
higher than that of the endogenous receptor, which is im-
portant for it to function effectively as a competitive domi-
nant negative inhibitor. The additional higher molecular
weight bands found in the MCF-7/TREZ clones, which may
have resulted from our use of a bicistronic vector, did not
interfere with the desired function of the truncated receptor
(see below).
Growth inhibition of epithelial cells provides a convenient
and relevant functional assay for measuring TGF-b sensitiv-
ity. Therefore, to evaluate the TGF-b responsiveness of the
MCF-7/TREZ and the MCF-7/EZ stable clones, cell prolifer-
ation of each clone was measured in the presence or ab-
sence of TGF-b for 5 days (Fig. 2). MCF-7/EZ clones retain
their TGF-b responsiveness and display 50% growth inhibi-
tion at 1 ng/ml TGF-b, whereas the MCF-7/TREZ clones
showed no growth-inhibitory effect at up to 3 ng/ml TGF-b.
The doubling times of the different clones in the absence of
exogeneous active TGF-b were not significantly different
from one another (data not shown), suggesting that insuffi-
cient amounts of active TGF-b are produced under standard
growth conditions to exert an autocrine antiproliferative ef-
fect. The loss of TGF-b sensitivity in the MCF-7/TREZ clones
indicates that the truncated TbR-II functions as a dominant
Fig. 1. All MCF-7 stable transfectants express full-length endogenous
TbR-II, but the truncated TbR-II is found only in MCF-7/TREZ clones. Cell
lysates were prepared and analyzed by Western blot (50 mg/lane) with
anti-TbR-II as the primary antibody. The epitope of this antibody consists
of amino acids 246–266, which are present in both the truncated and
endogenous receptors. Note that all clones express the full-length recep-
tor at Mr 85,000 and the MCF-7/TREZ clones express the truncated
receptor near Mr 38,000.
Fig. 2. Truncated TbR-II functions as a dominant negative mutation and
effectively blocks TGF-b signaling. Cells were counted and plated in a
96-well plate at 3000 cells/well. TGF-b was added to triplicate wells at
doses of 0, 0.3, 1.0, or 3.0 ng/ml, and cells were incubated at 37°C for 5
days. A colorimetric MTS reduction assay was conducted to determine
the relative number of viable cells in each well. Each clone served as its
own control, and values given are a percentage of the untreated control.
SDs of the triplicate samples averaged less than 3.5% of the mean. This
experiment was repeated three times with similar results.
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been documented for mink lung epithelial cells and cardiac
myocytes (13, 14).
TGF-b Signaling Alters TNF-a-induced Cytotoxicity.
Other investigators have shown that treatment of MCF-7
cells with TNF-a results in up-regulation of the production
and secretion of TGF-b by the treated cells (11). To evaluate
whether TGF-b signaling plays a functional role in TNF-a-
induced cytotoxicity, the MCF-7/EZ and MCF-7/TREZ
clones were treated with a wide range of TNF-a concentra-
tions for 5 days (Fig. 3). The TGF-b-responsive MCF-7/EZ
clones were highly sensitive to the cytotoxic effects of
TNF-a, characterized by an IC50 of 100 units/ml. In contrast,
the TGF-b-nonresponsive MCF-7/TREZ clones were rela-
tively resistant to TNF-a-induced cell death and displayed an
IC50 of 800 units/ml. This 8-fold increase in IC50 indicates
that TGF-b signaling via an autocrine loop does play a role in
facilitating TNF-a-induced cytotoxicity. To confirm that
TNF-a was causing cytotoxicity rather than simply growth
arrest, cells were assayed for their viability, as measured by
the ability to exclude trypan blue. These experiments verified
that TNF was indeed resulting in cell death. Specifically, the
viability of the TGF-b-responsive MCF-7/EZ clones after a
5-day treatment with 1000 units/ml TNF was 28.7 6 4.7%,
whereas the viability of the TGF-b-nonresponsive MCF-7/
TREZ clones was 60.0 6 7.6% (P 5 0.0002). We did not
observe the changes in cell shape or chromatin condensa-
tion typically associated with apoptosis, consistent with the
report of Ja ¨nicke et al. (15) that MCF-7 cells lack caspase-3
and therefore do not demonstrate DNA fragmentation or
visible morphology changes on TNF killing.
Autocrine TGF-b Signaling Does Not Affect the Expres-
sion Levels of TNF-RI or TRADD. The TNF-a cell death
pathway is initiated when TNF-a ligand binds its receptor
TNF-RI (p55), resulting in recruitment of TRADD to the cyto-
plasmic death domain of the receptor (12). To assess
whether TGF-b signaling affects the expression level of these
two proteins, Western analysis was conducted on cell ly-
sates of TGF-b-responsive MCF-7/EZ clones and TGF-b-
nonresponsive MCF-7/TREZ clones (Fig. 4). Equal levels of
the TNF-RI receptor were observed in all clones, whereas the
TRADD levels were nearly equivalent. We have also deter-
mined that the clones do not differ significantly with regard to
their expression of the second TNF-R, TNF-RII (Fig. 4C).
These data argue that TGF-b signaling has not significantly
altered the expression of these proteins and that the marked
difference between the MCF-7/TREZ and the MCF-7/EZ
clones in their sensitivity to TNF-a-induced cytotoxicity can-
not be attributed to changes in TNF-RI or TRADD protein
expression or to the ratio of TNF-Rs.
NF-kB Is Activated in Response to TNF-a in Both TGF-
b-responsive MCF-7/EZ Clones and TGF-b-nonrespon-
sive MCF-7/TREZ Clones. Having established that TGF-b
signaling has not significantly altered the expression of key
proteins involved in the early steps of TNF-a signaling, we
evaluated known mechanisms of resistance to TNF-a-
induced cell death. Many studies have shown that activation
of the transcription factor NF-kB can provide an antiapo-
ptotic signal, thereby promoting cell survival (16–18). More-
over, evidence in the literature has established that TGF-b
treatment can inhibit activation of NF-kB in certain systems
(19). To determine whether TGF-b is attenuating NF-kB ac-
tivity in MCF-7 cells, thereby resulting in enhanced sensitivity
to TNF-a-mediated cell death, NF-kB activity in nuclear ex-
tracts of MCF-7/EZ and MCF-7/TREZ clones after treatment
with TNF-a was measured by gel shift assay (Fig. 5A). The
levels of NF-kB activation in response to TNF-a are equiva-
lent in both TGF-b-responsive and -nonresponsive clones,
and the maximum activity appears to be reached within the
first hour of treatment. In addition to assaying NF-kB DNA
binding activity by gel shift, the transcriptional activity of
NF-kB was measured using a NF-kB-responsive luciferase
reporter construct (Fig. 5B). In agreement with the gel shift
data, the results of the luciferase reporter assays show that
the induction of NF-kB transcriptional activity in response to
TNF-a treatment is equal in the MCF-7/TREZ and MCF-7/EZ
clones. These results indicate that the effect of TGF-b on
Fig. 3. TGF-b signaling plays an active role in TNF-a induced cytotox-
icity. Cells were counted and plated in a 96-well plate at 3000 cells/well.
TNF-a was added to triplicate wells at doses ranging from 0 to 3000
units/ml, and the cells were incubated at 37°C for 5 days. A colorimetric
MTS reduction assay was conducted to determine the relative number of
viable cells in each well. Each clone served as its own control, and values
given are a percentage of the untreated control. The TGF-b-responsive
MCF-7/EZ clones show an average IC50 of 100 units/ml TNF-a, whereas
the TGF-b-nonresponsive MCF-7/TREZ clones have an average IC50 of
800 units/ml TNF-a. SDs of the triplicate samples averaged less than
3.5% of the mean. This experiment was repeated three times with similar
results.
Fig. 4. TGF-b does not affect expression of TNF-RI (p55) or TRADD. Cell
lysates were prepared, and 100 mg of protein per lane were loaded on a
10% SDS-PAGE gel. Western immunoblot analyses were carried out
using (A) anti-TNF-RI, (B) anti-TRADD, or (C) anti-TNF-RII as the primary
antibody.
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NF-kB activity. Additionally, these data emphasize that al-
though the TGF-b-nonresponsive MCF-7/TREZ clones are
resistant to the cytotoxic effects of TNF-a, they are still
capable of responding to TNF-a ligand and that certain
branches of the TNF-a signaling cascade remain as sensitive
as they are in the TGF-b-responsive MCF-7/EZ controls.
Loss of Autocrine TGF-b Signaling Up-Regulates Ex-
pression of Bcl-2 but Has No Effect on Bax and Bcl-XS/L.
It has been shown previously that the Bcl-2 family of proteins
is a key regulator of cell death induced by many stimuli and
that TGF-b signaling can alter the expression of Bcl-2 family
members in a variety of cell types (20–23), although breast
cancer cells have not been studied in this regard. To ascer-
tain whether or not TGF-b is altering the cell’s resistance to
TNF-a-induced cell death by modulating the expression of
Bcl-2 family members, Western analysis was conducted on
cell lysates of TGF-b-responsive MCF-7/EZ and TGF-b-
nonresponsive MCF-7/TREZ clones (Fig. 6). There were no
significant differences in the expression levels of Bax and
Bcl-X. However, all of the MCF-7/TREZ clones express high
levels of Bcl-2, whereas the MCF-7/EZ clones express much
lower levels of Bcl-2. Analysis of RNA from the clones for
expression of Bcl-2 mRNA showed analogous differences
between the MCF/EZ and MCF-7/TREZ cells (Fig. 6, E and
F). These data indicate that autocrine TGF-b signaling in
MCF-7 cells down-regulates Bcl-2 expression, thereby ren-
dering the cells sensitive to TNF-a-induced cytotoxicity.
When the TGF-b autocrine loop is no longer functional, as in
the MCF-7/TREZ clones, high levels of Bcl-2 expression
result, leading to increased resistance to TNF-a-induced cell
death.
Restoration of TGF-b Signaling Results in Down-
Regulation of Bcl-2 Expression. To further investigate the
effect of TGF-b on Bcl-2 expression in MCF-7 cells, we
restored TGF-b signaling to a subline of MCF-7 cells that had
lost its responsiveness to TGF-b. It has been documented
that through prolonged passage, sublines of MCF-7 cells
have arisen that are no longer responsive to TGF-b, often
with diminished cell surface expression of TGF-b receptors
Fig. 5. Autocrine TGF-b signaling does not alter basal levels or TNF-a
induced levels of NF-kB activity. A, cells were plated in 6-well plates and
treated on the following day with or without TNF-a at 10,000 units/ml for
1 or 4 h. Activation of NF-kB was measured by gel shift assay. Nuclear
extracts were harvested, and 2 mg of nuclear protein were incubated for
20 min with a radiolabeled double-stranded DNA oligonucleotide contain-
ing the consensus kB binding sequence and then electrophoresed on a
nondenaturing 4% polyacrylamide gel. Note: Lane 8 contains one-fifth the
amount of nuclear extract analyzed in the other lanes. B, cells were
transfected with the NF-kB-responsive luciferase reporter plasmid
p-55IgkLuc. The next day, the cells were treated with 0, 100, or 300
units/ml TNF-a for 20 h and then assayed for luciferase activity. Each bar
represents the average of duplicate lysates that were analyzed for lucif-
erase activity in triplicate. SDs of the triplicate samples averaged less than
4% of the mean. Statistical analysis indicates that TNF-induced NF-kB
activation in MCF-7/EZ clones is not significantly different from that in
MCF-7/TREZ clones (P . 0.6).
Fig. 6. Bcl-2 expression is up-regulated by loss of autocrine TGF-b
signaling in MCF-7 cells. Cell lysates were prepared, and 100 mg of protein
were loaded per lane of an SDS-PAGE gel. Western immunoblot analyses
were carried out using primary antibodies to various members of the Bcl-2
family of proteins. These data reveal no significant differences in the
expression of (A) Bax or (B) Bcl-X. However, in C, a large difference in
Bcl-2 expression in MCF-7/EZ versus MCF-7/TREZ clones is identified. D,
overexposure of the anti-Bcl-2 blot shown in C allows detection of the low
level of Bcl-2 protein expressed in the TGF-b-responsive MCF-7/EZ
clones. Reverse transcription-PCR of Bcl-2 mRNA expression after 32
cycles (E) and 38 cycles (F) demonstrates concordance between Bcl-2
protein and RNA expression levels.
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Clontech are not growth inhibited by TGF-b. Furthermore,
these cells are resistant to TNF-a-mediated cell death and
express a level of Bcl-2 comparable to that in the MCF-7/
TREZ cells (data not shown). Activation of the TGF-b signal
transduction cascade in these cells was achieved by trans-
fection of a novel expression construct for a chimeric protein
in which the cytoplasmic kinase domains of TbR-I and TbR-II
are tethered to each other, thereby bypassing any receptor
defect (25). In three separate transient transfections of this
construct, in which transfection efficiencies of 30–40% were
documented by parallel transfections of an expression plas-
mid for green fluorescent protein, Bcl-2 protein levels were
reduced to 50% of transfected controls, on average (P 5
0.027). Fig. 7 includes Western analysis data from one such
experiment. Although these transient transfection experi-
ments do not indicate the mechanism by which TGF-b sig-
naling affects Bcl-2 levels, they support the notion that the
elevated levels observed in the MCF-7/TREZ clones resulted
from derepression of Bcl-2 expression as a consequence of
loss of TGF-b responsiveness.
Discussion
Considerable progress has been achieved in recent years
toward increasing our understanding of pathophysiological
mechanisms of cell death, especially in the elucidation of the
principal mediators and regulators of apoptosis. Numerous
investigators, in the course of characterizing early changes in
gene expression during physiological and drug-induced cell
death in various epithelial tissues and cancers, have noted a
dramatic upsurge in the expression of TGF-b (5–7, 9, 26–29).
This led us to ask whether TGF-b was an integral component
of the killing process and, if so, whether the TGF-b autocrine
pathway of cells was protective or alternatively enhanced cell
death under these circumstances. We focused our investi-
gation on the cytotoxicity of TNF-a toward human breast
cancer MCF-7 cells because the kinetics and magnitude of
TGF-b induction after exposure to TNF-a, but before cell
death, have been well documented (11). The studies re-
ported here serve to highlight and characterize an important
role for TGF-b in TNF-a-mediated killing, possibly via the
repression of Bcl-2 expression.
We tested the hypothesis that TGF-b signaling was an
important feature of TNF-a killing by stable transfection of
MCF-7 cells, which were responsive to both cytokines, with
a dominant negative truncated TbR-II, thereby blocking func-
tional signal transduction by TGF-b. We observed that
MCF-7 cells transfected with control vector (MCF-7/EZ
clones) retained responsiveness to TGF-b and susceptibility
to TNF-a-mediated cytotoxicity, whereas the cells trans-
fected with the truncated TGF-b receptor (MCF-7/TREZ
clones) were unresponsive to TGF-b and had acquired re-
sistance to TNF-a killing. Our findings differ from those of
Danforth and Sgagias (11), who, in similarly motivated ex-
periments, determined that a neutralizing anti-TGF-b anti-
body had no effect on TNF-a-induced growth inhibition of
MCF-7 cells. A logical explanation for this apparent discrep-
ancy is that exogenously added antibody resulted in incom-
plete neutralization of TGF-b because it could not gain ac-
cess to all of the TGF-b. For instance, some TGF-b may be
sequestered in the compartment between the cells and the
culture dish.
NF-kB is a downstream mediator of many of the biological
activities of TNF-a. After TNF binding to cell surface recep-
tors, NF-kB is liberated from its binding to IkB in the cyto-
plasm and translocates to the nucleus to effect changes in
gene expression. Of interest, some of the genes that are
induced by NF-kB in response to TNF are protective of
TNF-mediated cytotoxicity (16, 18, 30). Indeed, constitutive
activation of NF-kB has been associated with marked resist-
ance to killing by TNF-a (17). We therefore performed exper-
iments examining the induction of NF-kB activity in response
to TNF-a and observed no differences among our clones
with regard to the activation or functional activity of NF-kB,
implicating other mechanisms for the TNF resistance of our
TGF-b-nonresponsive cell clones. It is worth emphasizing
that the ability of the MCF-7/TREZ cells to bind TNF-a and
properly transduce its signal was not altered, indicating that
the overexpression of the dominant negative TbR-II protein
did not disrupt TNF-R function.
Further investigation into the molecular mechanism of our
basic observation has identified Bcl-2 as a potential inter-
mediary of the effect of TGF-b. Two prior groups have eval-
uated the ability of Bcl-2 to protect breast cancer cells from
TNF killing. Ja ¨a ¨ttela ¨ et al. (31) reported that increased ex-
pression of Bcl-2 in MCF-7 cells, achieved by transfection of
a Bcl-2 expression construct, resulted in marked resistance
to cytolysis by either TNF or Fas. Vanhaesebroeck et al. (32)
observed only a modest reduction in susceptibility to TNF-
induced cytotoxicity in association with increased expres-
sion of Bcl-2. Some of the observed differences may relate to
the use of MCF-7 cell variants that are in fact quite distinct in
many respects. Indeed, a recent direct comparison of three
MCF-7 variants revealed strikingly different degrees of TNF-
a-induced apoptosis, some of which directly correlated with
differences in basal expression of Bcl-2 (33). The importance
of clonal variants of MCF-7 cells with regard to responsive-
ness to TGF-b has been noted by many investigators and
Fig. 7. Restoration of TGF-b signaling results in a decrease in Bcl-2
expression. A TGF-b-nonresponsive subline of MCF-7 cells was trans-
fected with plasmid pXF1042 or the empty vector control, EZ. The
pXF1042 construct expresses a chimeric protein containing the cytoplas-
mic kinase-containing domains of TbR-I and TbR-II, which has been
shown to activate TGF-b signaling in the absence of ligand (25). Parallel
transfections of an expression plasmid for green fluorescent protein,
pEGFP-N3 (Clontech), yielded estimated transfection efficiencies of 30–
40%. Protein lysates were harvested 3 days after the transfection, and
Bcl-2 expression level was analyzed by Western blot, loading 30 mgo f
total protein per lane.
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ization of TbR-II in some nonresponsive clones (34). Our data
suggest that some of the clonal differences reported by
others in Bcl-2 expression and perhaps in TNF killing as well
reflect underlying differences in TGF-b responsiveness
among MCF-7 variants.
Our observations may also be relevant to recently pub-
lished studies involving a variety of cell systems, including
gliomas, Schwann cells, and endometrial epithelial cells, re-
porting a synergistic proapoptotic effect of TGF-b when
combined with TNF-a or Fas (35–37). Furthermore, the TGF-
b-inducing effect of agents such as vitamin D may explain
reports of their ability to potentiate the cytotoxic effect of
TNF-a (38). Clearly, however, some cell systems have dem-
onstrated TGF-b-mediated attenuation of cytotoxicity by
TNF-a, underscoring the fact that complex pathways will
likely yield distinct results in different cell types (39, 40).
Some of the differences in reported effects of TGF-b on
TNF-a cytotoxicity may derive from cell type-specific effects
of TGF-b on expression of Bcl-2. For instance, down-regu-
lation of Bcl-2 after exposure to TGF-b has been observed in
leukemic cell lines, colonic adenoma cells, ovarian carci-
noma cells, and umbilical vein endothelial cells (21–23, 41,
42). In contrast, TGF-b has been reported to increase the
level of Bcl-2 expression in neuronal cells and rheumatoid
synovial cells (20, 43). Our observation of concordance be-
tween Bcl-2 mRNA and protein expression among our
clones indicates that the effect of TGF-b is not mediated
through enhanced Bcl-2 protein turnover or attenuation of
translation of the Bcl-2 mRNA. We have transfected our cell
clones with a human Bcl-2 promoter construct containing the
full 59 untranslated region and more than 2.5 kb of upstream
promoter sequence, driving the expression of luciferase (44).
In two experiments, we noted no significant differences in
promoter activity among the clones or effect of exogenous
TGF-b on luciferase expression of transfected MCF-7/EZ
cells (data not shown). This suggests that the effect of TGF-b
on Bcl-2 expression in MCF-7 cells is either posttranscrip-
tional, i.e., mediated by a destabilization of Bcl-2 mRNA, or
involves transcriptional regulatory elements that are not con-
tained within this promoter construct.
Dominant repression of Bcl-2 by TGF-b may be an impor-
tant element in a number of physiological processes, includ-
ing apoptosis of the mammary gland during the immediate
postlactational period (26, 45). Furthermore, loss of the nor-
mal TGF-b/Bcl-2 axis of repression may have important im-
plications in the development and treatment of some forms
of malignancy. Disruption of TGF-b signaling, either by loss
of receptor function (46–49) or due to defective downstream
signal propagation (50–52), has been reported in a wide
range of cancers. Truncation of TbR-II via somatic mutation
is an early and likely determining event in colon carcinogen-
esis in the setting of the hereditary nonpolyposis colorectal
cancer syndrome (53). Bcl-2 can protect cells from a wide
range of injurious assaults, including those mediated by var-
ious forms of chemotherapy (54, 55). Although investigators
have not yet correlated absence of functional TGF-b signal-
ing with resistance to anticancer therapy, such as might well
accompany a presumed derepression of Bcl-2 expression,
this consequence of the loss of TGF-b responsiveness by
tumors may represent its most pernicious manifestation.
Materials and Methods
Plasmid DNA Construction and Isolation. We used a bi-
cistronic plasmid strategy (56) to obtain stable transfectants
overexpressing a truncated TbR-II. To accomplish this, we
constructed a plasmid, designated TREZ, that directs tran-
scription of a bicistronic mRNA containing the truncated
TbR-II followed by the internal ribosomal entry site of the
encephalomyocarditis virus, upstream of the coding se-
quence of the zeocin resistance selectable marker gene. This
bicistronic coding sequence was subcloned into the pRK5
expression vector (Genentech), which uses the cytomegalo-
virus promoter/enhancer to drive expression. Specifically,
the 830-bp NcoI-BglII fragment of the TbR-II cDNA clone
H2-3FF (57) was subcloned into the EcoRI-BamHI sites of
pRK5. Brand and Schneider (13) have reported that trunca-
tion of TbR-II at this BglII site results in the generation of a
kinase-deficient dominant negative mutant receptor. The re-
sulting plasmid was cut at XbaI and SalI sites downstream of
the truncated TbR-II sequence and used in a three-way
ligation for the addition of the 599-bp XbaI-NcoI fragment
from LZIN (56) containing the internal ribosomal entry site
and the 429-bp NcoI-SalI fragment from pZeoSV (Invitrogen)
containing the coding sequence for the zeocin resistance
gene. The control plasmid, designated EZ, was created by
removal of the truncated receptor sequence from the TREZ
plasmid by EcoRI digestion and reclosure by intramolecular
ligation. The expression plasmid designated pXF1042, which
has been shown to bypass receptor defects and induce
ligand-independent TGF-b signaling in cells, was obtained
from Dr. Rik Derynck (University of California, San Francisco,
CA; Ref. 25). All plasmid DNAs were purified using a DNA
column chromatography kit (Qiagen).
Cell Culture and Transfection. The human breast cancer
cell line MCF-7 was obtained from American Type Culture
Collection. For the experiments with the pXF1042 plasmid, a
clone of MCF-7 cells from Clontech (MCF-7 Tet/Off) was
used. Cells were maintained in DMEM:Ham’s F-12 supple-
mented with 10% fetal bovine serum, 2.5 mML -glutamine,
100 IU/ml penicillin, and 100 mg/ml streptomycin at 37°C,
5% CO2. To generate stable transfectants overexpressing
the truncated TbR-II, MCF-7 cells in 10-cm dishes were
transfected with 15 mg of the expression plasmid TREZ or
control plasmid EZ by calcium phosphate-mediated trans-
fection (58). Forty-eight h after transfection, the cells were
trypsinized and split into 10-cm dishes with selective media
containing 50 mg/ml zeocin (Invitrogen). Zeocin-resistant
clones were isolated, expanded, and assayed for expression
of the transfected gene by Western blot analysis.
Cell Proliferation and Cytotoxicity Assays. Cells were
trypsinized, counted on a hemocytometer, and then plated in
a 96-well plate in triplicate at 3000 cells/well in the same
serum-containing medium used for routine cell culture. After
6 h, recombinant human TNF-a or TGF-b1 (R&D Systems)
was added to each well at various concentrations. The plates
were incubated at 37°C, 5% CO2 for 5 days. The relative
number of viable cells in each well was determined by MTS
114 Autocrine TGF-b Signaling Enhances TNF-a Cytotoxicityreduction assay using the Celltiter 96 kit (Promega) accord-
ing to the manufacturer’s instructions. In some experiments,
cell viability was determined by trypan blue exclusion. Cells
were trypsinized and mixed with trypan blue, and the number
of blue cells and trypan blue-excluding cells was determined
by counting cells on a hemocytometer. Triplicate samples
were analyzed.
Gel Shift Assay. Electrophoretic mobility shift assays of
nuclear NF-kB were conducted as described by Barchowsky et
al. (59). Cells were plated in 35-mm wells in triplicate. The next
day, cells were treated with 10,000 units/ml TNF-a f o r1o r4h
or left untreated. Nuclear extracts were harvested, and protein
content was determined by the BCA protein assay (Pierce). The
gel shift probe was a double-stranded NF-kB consensus oli-
gonucleotide (59-AGTTGAGGGGACTTTCCCAGGC-39; Pro-
mega) labeled at the 59 end with
32P (58). Two mg of nuclear
protein were incubated with 2 3 10
5 cpm of 59-
32P-labeled
probe and then resolved by electrophoresis in a 4% acrylamide
gel under nondenaturing conditions. The gel was then dried and
exposed to autoradiographic film.
Luciferase Reporter Assay. Cells were plated in 10-cm
dishes and transfected with the NF-kB-responsive p-55IgkLuc
plasmid (60) by LipofectAMINE (Life Technologies, Inc.). The
following day, each 10-cm dish was trypsinized, and the cells
were divided equally among the wells of a 6-well plate. Cells
were treated in duplicate with 0, 100, or 300 units/ml TNF-a at
37°C for 20 h. To prepare lysates, cells were washed three
times with cold PBS, suspended in 200 ml of lysis buffer (1%
Triton X-100, 25 mM glycylglycine, 15 mM MgSO4,4m M EGTA,
a n d1m M DTT), and then centrifuged at 14,000 3 g for 5 min at
4°C. The supernatant was assayed for luciferase activity in
triplicate in a luminometer. This assay was conducted in a
96-well plate format, with each well containing 20 ml of lysate,
20 ml of lysis buffer, and 145 ml of assay buffer (25 mM glycyl-
glycine, 15 mM potassium phosphate, 15 mM MgSO4,4m M
EGTA, 2 mM ATP, and 1 mM DTT) with the addition of 40 mlo f
luciferin solution (400 mM luciferin and 25 mM glycylglycine) at
the time each well was read. Luciferase activity of each sample
was normalized to the protein content of the lysates, which was
assessed by the BCA protein assay (Pierce).
Western Blot Analysis. Cells were grown in 10-cm
dishes, washed twice with cold PBS, and scraped in 1 ml of
PBS containing protease inhibitors (9.5 mg/ml aprotinin, 10
mg/ml leupeptin, and 1 mM pefabloc). The cells were trans-
ferred to a microfuge tube and then centrifuged at 150 3 g
to pellet the cells. The cell pellet was resuspended in lysis
buffer [50 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 0.5%
NP40] containing the same protease inhibitors. The lysates
were shaken on ice for 20 min, followed by centrifugation at
16,000 3 g for 10 min at 4°C to pellet insoluble material. The
supernatant was transferred to a microfuge tube and stored
at 270°C. Protein concentrations were determined by the
BCA assay. Cell lysates were resolved by SDS-PAGE and
transferred to nitrocellulose membranes. The membranes
were blocked in 5% milk in TBS and incubated with primary
antibody diluted in 5% milk in TBST. After three washes in
5% milk in TBST, the blots were incubated with horseradish
peroxidase-conjugated secondary antibody (Jackson Labo-
ratories) diluted 1:2000, washed three times in 5% milk in
TBST, rinsed once in TBS, and then developed by enhanced
chemiluminescence (Amersham). All experiments involving
Western blot analyses were performed at least three times,
and one representative blot was used for the relevant figures.
Antibodies. The antibodies used were as follows: (a) for
TbR-II, L-21 (Santa Cruz Biotechnology; 100 mg/ml; used at
0.1 mg/ml; 1:1000); (b) for TNF-RI, 1995-01 (Genzyme; 1
mg/ml; used at 10 mg/ml; 1:100); (c) for TNF-RII, 1888-01
(Genzyme; 1 mg/ml; used at 10 mg/ml; 1:100); (d) for TRADD,
T50320 (Transduction Laboratories; 250 mg/ml; used at 1
mg/ml; 1:250); (e) for Bax, N-20 (Santa Cruz Biotechnology;
100 mg/ml; used at 0.13 mg/ml; 1:750); (f) for Bcl-XS/L, M-125
(Santa Cruz Biotechnology; 200 mg/ml; used at 2 mg/ml;
1:100); (g) for Bcl-2, M0887 (Dako; 320 mg/ml; used at 0.16
mg/ml; 1:2000); and (h) for actin, N350 (Amersham; 300 mg/
ml; used at 0.075 mg/ml; 1:4000).
RNA Preparation and Analysis. Total RNA was prepared
from cells using the Trizol reagent according to manufactur-
er’s instructions (Life Technologies, Inc.), and 2 mg of total
RNA were used for synthesis of cDNA using random hex-
amer primers and Moloney murine leukemia virus reverse
transcriptase. Equivalent cDNA synthesis between the
clones was confirmed with actin-specific primers. PCR of
Bcl-2 cDNA was performed with 0.5 mM primers (59-
ACGACTTCTCCCGCCGCTACC; 59-GTACAGTTCCAC-
AAAGGCATCC) at an annealing temperature of 60°C for 30 s
and extension at 72°C for 30 s each cycle. Five ml of reverse
transcription reaction were used as template. These primers
span an intron and yield a 302-bp product, and no product
was obtained if reverse transcriptase was ommited from the
cDNA synthesis step.
Statistical Analysis. Statistical significance of the exper-
imental data was determined using the two-tailed, unpaired
Student’s t test. P , 0.05 was considered significant.
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